RxDoctor Payments Data

Mohammed Baig, MD

General Practice · Plantation, FLNPI 1043209125

Payments from drug & device makers

$668in general payments, 2019–2025

Across 28 payments — averaging $23.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$288
  • E.r. Squibb & Sons, L.L.C.$113
  • Biotronik Inc.$46
  • Cequr Corporation$45
  • Pfizer$31
  • Lilly USA, LLC$26
  • plus $118 from 6 others

What the payments were for

  • Food & beverage$668100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$668 in reported general payments places this provider in the 70th percentile of 6,901 general practice providers in Florida.

See all general practice providers in Florida

Medicare billing

Part B allowed, 2024
$69,772
Medicare patients
128
Services billed
705

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban27$25,376
Cephalexin22$643
Ezetimibe12$642
Amlodipine Besylate104$569
Atorvastatin Calcium81$549
Valsartan26$453
Insulin SyringeSyringe And Needle,insulin,1ml11$436
Losartan Potassium65$416
Famotidine20$413
Gabapentin39$375
Albuterol Sulfate HfaAlbuterol Sulfate13$334
Nifedipine ErNifedipine21$281
Lisinopril44$263
Glipizide37$250
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen15$243

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$31$25,37627 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 6,901 general practice providers in Florida.

Other general practice in Plantation

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →